Levent Kabasakal
Levent Kabasakal is an expert in Nuclear medicine at Istanbul University (Turkey). As of August 2026, ScienceLeadR ranks Levent Kabasakal in the top 1% of experts in Turkey for Prostatic Diseases and Genital Diseases, Male. Levent Kabasakal has authored 215 publications, the most recent in 2026, and is an investigator in 1 clinical trial, 1 of them ongoing. SLR score: 635 (community average: 125). How the SLR is computed.
LeadR Profile
Nuclear medicine
Subspecialties: Radiotherapy - Oncology - Urology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1988 - 2026
Number : 215
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| The role of 68Ga-FAPi PET/CT in Staging and Restaging of Breast Cancer Subtypes with Limited 18F-FDG Uptake. PMID 42609054 — breast neoplasms, tomography, neoplasms, positron emission tomography computed tomography, fluorodeoxyglucose f18, neoplasm metastasis, breast, carcinoma, lobular | Mol Imaging Radionucl Ther | 2026 | 0 |
| Beyond conventional maging: the diagnostic performance of [ 68Ga]Ga-Trivehexin PET/CT for detecting hyperfunctioning parathyroid tissue in primary hyperparathyroidism. PMID 42113418 — radiotherapy, positron emission tomography computed tomography, hyperparathyroidism, primary, calcium, tissues, wounds and injuries, hyperparathyroidism, radionuclide imaging | Ann Nucl Med | 2026 | 0 |
| Modulation of Amyloid and Tau Pathology by Empagliflozin in a High-Fat Diet and Streptozotocin-Induced Type 2 Diabetes-Associated Alzheimer's Model. PMID 41986822 — diabetes mellitus, sodium-glucose transporter 2 inhibitors, insulin, acetylcholinesterase, neurons, pathology, diet, high-fat, diet, streptozocin, neurosciences, therapeutics, amyloid, nervous system, diabetes mellitus, type 2 | Eur J Neurosci | 2026 | 0 |
| The role of PSMA PET/CT imaging in identifying low-risk prostate cancer candidates for active surveillance after biopsy. PMID 41762043 — neoplasms, prostate, biopsy, positron emission tomography computed tomography, prostatic neoplasms | Expert Rev Anticancer Ther | 2026 | 0 |
| [ 68Ga]Ga-PSMA PET/CT in active surveillance: From imaging to informed decision-making - a "Whistling Arrow" perspective. PMID 41733628 — decision making, positron emission tomography computed tomography | Eur J Nucl Med Mol Imaging | 2026 | 0 |
Clinical Studies 1
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Study of PSMA PET CT Imaging to Help Select Men With Low Risk Prostate Cancer for Active Surveillance NCT07168616 — neoplasms, prostate, biopsy, positron emission tomography computed tomography, prostatic neoplasms, diagnosis, men | N/A | Recruiting | 2025 |
LeadR Networks
Main global connection map